Average Insider

Where insiders trade, we follow

$TMO
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Healthcare
Sector
Medical - Diagnostics & Research
Industry
Marc N. Casper
CEO
125000
Employees
$474.39
Current Price
$198.06B
Market Cap
52W Low$385.46
Current$474.3934.4% above low, 65.6% below high
52W High$643.99

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00--All Sells
Sells11$802,535.801,607
1 monthBuys00--All Sells
Sells234$7,939,285.8115,607
2 monthsBuys00--All Sells
Sells335$8,155,765.8116,007
3 monthsBuys00--All Sells
Sells335$8,155,765.8116,007
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Mar 3, 2026
CASPER MARC N
Director
Sale360$495.29$178,304.40View Details
Mar 3, 2026
CASPER MARC N
Director
Sale480$496.84$238,483.20View Details
Mar 3, 2026
CASPER MARC N
Director
Sale680$498.14$338,735.20View Details
Mar 3, 2026
CASPER MARC N
Director
Sale240$499.75$119,940.00View Details
Mar 3, 2026
CASPER MARC N
Director
Sale382$500.55$191,210.10View Details
Mar 3, 2026
CASPER MARC N
Director
Sale360$501.95$180,702.00View Details
Mar 3, 2026
CASPER MARC N
Director
Sale120$502.59$60,310.80View Details
Mar 3, 2026
CASPER MARC N
Director
Sale120$504.06$60,487.20View Details
Mar 3, 2026
CASPER MARC N
Director
Sale448$506.74$227,019.52View Details
Mar 3, 2026
CASPER MARC N
Director
Sale931$507.90$472,854.90View Details
Mar 3, 2026
CASPER MARC N
Director
Sale759$508.95$386,293.05View Details
Mar 3, 2026
CASPER MARC N
Director
Sale120$509.62$61,154.40View Details
Mar 4, 2026
CASPER MARC N
Director
Sale447$509.89$227,920.83View Details
Mar 4, 2026
CASPER MARC N
Director
Sale678$510.71$346,261.38View Details
Feb 9, 2026
Pettiti Gianluca
Executive Vice President
Sale400$541.20$216,480.00View Details
65 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Jan 29, 2026
EPS
Estimated$6.44
ActualN/A
Revenue
Estimated$11.88B
ActualN/A
Version: v26.3.23